166 related articles for article (PubMed ID: 28890729)
21. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories.
Mendez P; Dang J; Kim JW; Lee S; Yoon JH; Kim T; Sailey CJ; Jablons DM; Kim IJ
Int J Oncol; 2016 Jul; 49(1):235-42. PubMed ID: 27121194
[TBL] [Abstract][Full Text] [Related]
22. Next-generation sequencing to guide cancer therapy.
Gagan J; Van Allen EM
Genome Med; 2015; 7(1):80. PubMed ID: 26221189
[TBL] [Abstract][Full Text] [Related]
23. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
24. Effective quality management practices in routine clinical next-generation sequencing.
de Abreu FB; Peterson JD; Amos CI; Wells WA; Tsongalis GJ
Clin Chem Lab Med; 2016 May; 54(5):761-71. PubMed ID: 26872315
[TBL] [Abstract][Full Text] [Related]
25. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.
Oberg JA; Glade Bender JL; Sulis ML; Pendrick D; Sireci AN; Hsiao SJ; Turk AT; Dela Cruz FS; Hibshoosh H; Remotti H; Zylber RJ; Pang J; Diolaiti D; Koval C; Andrews SJ; Garvin JH; Yamashiro DJ; Chung WK; Emerson SG; Nagy PL; Mansukhani MM; Kung AL
Genome Med; 2016 Dec; 8(1):133. PubMed ID: 28007021
[TBL] [Abstract][Full Text] [Related]
26. Development and Analytical Validation of a Targeted Next-Generation Sequencing Panel to Detect Actionable Mutations for Targeted Therapy.
Wang D; Ma K; Deng W; Li J; Xiang S; Zhang Y; Fu Y; Dai H; Huang B
Onco Targets Ther; 2021; 14():2423-2431. PubMed ID: 33854338
[TBL] [Abstract][Full Text] [Related]
27. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens.
Hadd AG; Houghton J; Choudhary A; Sah S; Chen L; Marko AC; Sanford T; Buddavarapu K; Krosting J; Garmire L; Wylie D; Shinde R; Beaudenon S; Alexander EK; Mambo E; Adai AT; Latham GJ
J Mol Diagn; 2013 Mar; 15(2):234-47. PubMed ID: 23321017
[TBL] [Abstract][Full Text] [Related]
28. Digital Sorting of Pure Cell Populations Enables Unambiguous Genetic Analysis of Heterogeneous Formalin-Fixed Paraffin-Embedded Tumors by Next Generation Sequencing.
Bolognesi C; Forcato C; Buson G; Fontana F; Mangano C; Doffini A; Sero V; Lanzellotto R; Signorini G; Calanca A; Sergio M; Romano R; Gianni S; Medoro G; Giorgini G; Morreau H; Barberis M; Corver WE; Manaresi N
Sci Rep; 2016 Feb; 6():20944. PubMed ID: 26864208
[TBL] [Abstract][Full Text] [Related]
29. Clinical next-generation sequencing in patients with non-small cell lung cancer.
Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
[TBL] [Abstract][Full Text] [Related]
30. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
[TBL] [Abstract][Full Text] [Related]
31. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay.
Beaubier N; Tell R; Lau D; Parsons JR; Bush S; Perera J; Sorrells S; Baker T; Chang A; Michuda J; Iguartua C; MacNeil S; Shah K; Ellis P; Yeatts K; Mahon B; Taxter T; Bontrager M; Khan A; Huether R; Lefkofsky E; White KP
Oncotarget; 2019 Mar; 10(24):2384-2396. PubMed ID: 31040929
[TBL] [Abstract][Full Text] [Related]
32. Validation and Clinical Applications of a Comprehensive Next Generation Sequencing System for Molecular Characterization of Solid Cancer Tissues.
Dehghani M; Rosenblatt KP; Li L; Rakhade M; Amato RJ
Front Mol Biosci; 2019; 6():82. PubMed ID: 31681791
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
34. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
[TBL] [Abstract][Full Text] [Related]
35. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
36. Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra
White T; Szelinger S; LoBello J; King A; Aldrich J; Garinger N; Halbert M; Richholt RF; Mastrian SD; Babb C; Ozols AA; Goodman LJ; Basu GD; Royce T
Oncotarget; 2021 Apr; 12(8):726-739. PubMed ID: 33889297
[TBL] [Abstract][Full Text] [Related]
37. Robustness of Next Generation Sequencing on Older Formalin-Fixed Paraffin-Embedded Tissue.
Carrick DM; Mehaffey MG; Sachs MC; Altekruse S; Camalier C; Chuaqui R; Cozen W; Das B; Hernandez BY; Lih CJ; Lynch CF; Makhlouf H; McGregor P; McShane LM; Phillips Rohan J; Walsh WD; Williams PM; Gillanders EM; Mechanic LE; Schully SD
PLoS One; 2015; 10(7):e0127353. PubMed ID: 26222067
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
39. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.
Laosinchai-Wolf W; Ye F; Tran V; Yang Z; White R; Bloom K; Choppa P; Labourier E
J Clin Pathol; 2011 Jan; 64(1):30-6. PubMed ID: 21030527
[TBL] [Abstract][Full Text] [Related]
40. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
